Brief Review on Novel Technology in Breast Cancer Chemotherapy

Abstract

Breast cancer is cancer that develops from breast tissue. Breast cells contain receptors for the two types of hormones estrogen and progesterone. They also contain receptors for a protein called HER2, which induce normal cell growth. Around two out of three women with breast cancer have cells that bear receptors for estrogen and progesterone, and just about 20–30% of breast cancers have too many HER2 receptors. Exploitation chemotherapy to treat triple negative breast cancer is still an efficient option. Triple negative breast cancer can be more assertive and challenging to treat. Also, the cancer is more liable to spread and occur. The treatment model for patients with triple-negative breast cancer (TNBC) is set to go through an impressive transformation, as standard chemotherapeutic approach is formed and novel antibody-drug conjugates (ADCs) are formulated. The selection of therapeutic targets is a critical aspect of antibody-drug conjugate research and development. Several methods of identification of antibody-drug-conjugate molecules are by preformulation study, formulation development, characterization linkers and cytotoxic drugs.

Keywords: Breast cancer, cytotoxic, antibody-drug conjugate

Cite this Article

Puja Kumari, Jain Sourabh D, Jayanti Mukherjee et al. Brief Review on Novel Technology in Breast Cancer Chemotherapy. Research & Reviews: Journal of Oncology and Hematology. 2018; 7(2): 22–26p.